Title of your presentation:
Advances in the Diagnosis and Treatment of Adenoid Cystic Carcinoma and Other Salivary Gland Cancers
Recent advances in our understanding of the molecular biology underlying adenoid cystic carcinoma as well as several other key salivary gland cancers have led to improved diagnostic tools as well as new therapeutic options for patients. Combined with the increasingly popular Milan reporting system, these advances are also enhancing the overall effectiveness of salivary gland FNA.
Dr. Faquin is the Chief of Otolaryngologic Pathology at the Massachusetts Eye and Ear and a subspecialist in Head and Neck Pathology & Cytopathology at the Massachusetts General Hospital in Boston. He is Professor of Pathology at Harvard Medical School, and is recognized for his contributions to the study of thyroid, salivary gland, and HPV-related cancers of the head and neck. He has authored over 290 peer-reviewed publications, and has co-authored books on head and neck cytohistology, salivary gland cytopathology, and thyroid cytopathology. Dr. Faquin is the Editor-in-Chief for Cancer Cytopathology which is one of the 3 journals of the American Cancer Society. He is a co-author of the Bethesda System for Reporting Thyroid Cytopathology, co-chair of the College of American Pathologists Evidence-Based Guidelines Committee for the testing of head and neck squamous cell carcinomas for high-risk HPV, and co-chair of the Milan System for Reporting Salivary Gland Cytopathology sponsored by the ASC and IAC.
Title of your presentation:
Genomic markers in Sarcomas in daily practice - From molecular diagnosis to therapeutic target
In the novel context of precision medicine our laboratory develops and implements a panel of technologies and innovative molecular tools. In daily practice, these new genomic investigations participate to diagnostic orientation and/or to therapeutic stratification strategy and are now mandatory for frequent pathologies management such as rare pediatric tumors, sarcomas, which are therefore analyzed in a more centralized way.
EDUCATION / POSITIONS
1998: Post-graduate diploma (M2) in Oncogenesis. Laboratory of François SIGAUX at the St Louis Hospital Paris
2002: PhD in molecular biology and genetics delivered by the Paris VII University of Paris (France) staged in the laboratory of François SIGAUX at the St Louis Hospital Paris, France. Summa Cum Laude
2003: Position CIT Program in Olivier DELATTRE’s laboratory Research Center, Institut Curie, Paris
Dec 2003: Recruited as Coordinator of Genetic Somatic Unit Institut Curie Hospital, Paris. Deputy since 2016
2009: Europeen DIU Molecular Cytogenetics Paris V University of Paris (France)
2012/2017: Hospital Habilitation for human genetics characterization in medical practice. Biomedical Agency Renewed 2017/2022
Sarcomas, pediatric tumors, Ewing sarcoma, rare sarcomas, cytogenetics, genomics, genetics, translocations, Molecular Biology, Next Generation Sequencing (WES, RNASeq Panels…)
MEMBERSHIP, NETWORK, EXPERT EVALUATION
Member of the Institut Curie BioPathology committee.
Deputy of Curie INCa Plateform
Member Molecular Biology Board SHIVA (01/02), SAFIR02, MAPPYACTS, Molecular Precision MTB (since 2014).
Member of the French sarcoma group GSF-GETO
Member of the MMT group of French society for pediatric cancer (SFCE)
Member of the French Cytogeneticists associaction (ACLF)
GIRCI SOHO ; AAP-Bio fondation Rares Deseases (3/4 twice a year); JCO, Cancer Research, Sarcoma, Clinical Cancer Research
France Vietnam Collaboration
Educationnal programs (Academic Master1/2, International courses and lecture 20h/year)
MAJOR SCIENTIFIC PUBLICATIONS OVER THE LAST YEARS
H-index: 38; i10-index: 72; more than 125 publications
1: Watson S et al. J Pathol. 2018
2: Sheffield NC et al. Nat Med. 2017
3. Pincez T, et al. Pediatr Blood Cancer. 2016
4. Le Loarer, F Nat Genet 2015
5. Tirode, F. et al. Cancer Discov. 2014
6. Postel-Vinay et al. Nature Genetics 2012
7. Pierron, G et al. Nature Genetics 2012
Title of your presentation:
I'm a Professor and Section Chief of Head and Neck Pathology at the University of Texas M.D. Anderson Cancer Center and the Director of the Head and Neck Pathology Fellowship. I also head the head and neck sub-specialty training program I'm a member of several editorial boards of pathology, oncology and head and neck medical journals. I hold the Kenneth D. Muller endowed professorship for cancer research and the recipient of several national and international honors in the field of head and neck cancer. I'm also a member of national and international committees and cooperative groups in head and neck tumors. I've authored and co-authored 610 articles, 55 editorials and 10 book chapters on pathology of the head and neck. My main research efforts are focused on molecular genetic characterization of head and neck and salivary carcinomas and biomarker integration in clinical management of patients with these tumors.
Title of your presentation:
HPV primary screening pathways; negotiating the international landscape
Current (substantive) post: 2012-ongoing
Consultant Clinical Scientist (Virology).
Director, Scottish HPV Reference Laboratory & R and D Lead for Scottish Bacterial STI Reference Laboratory, Royal Infirmary of Edinburgh, NHS Lothian.
Honorary position(s) – Lead for HPV Research Group, Division of Pathology, University of Edinburgh. Lecturer, University of Glasgow, Institute of Infection Immunity and Inflammation.
Associate Clinical Scientist then Clinical Scientist Specialist Virology Centre (City Hospital and Royal Infirmary of Edinburgh)
Deputy Director Scottish HPV Reference Laboratory, Royal Infirmary of Edinburgh
BSc, Hons Microbiol University of Glasgow
PhD, Molecular and Cell Biology, University of Aberdeen
• Registered with the Health Professions Council (Microbiology)- Registration No. CS13108
• Fellow of the Royal College of Pathologists (Virology)
Overview of current position/experience
• As Director of SHPVRL, I am accountable for delivery of a service to the NHS in Scotland with respect to the surveillance, control, diagnosis and management of HPV infection. SHPVRL is funded by NHS National Services Scotland with streams of work funded by Health Protection Scotland, the Scottish Cervical Screening programme and National Services Division (Scotland). Other service level agreements with external agencies/entities are also in place. The SHPVRL is accredited for HPV testing by the UK Accreditation Service and is also accepted as a pre-qualification laboratory for HPV testing by the World Health Organisation.
• Since 2012 I have been lead for the HPV research group in the University of Edinburgh, Division of Pathology, Queens Medical Research Institute, where the Scottish HPV Archive - a biobank of over 30,000 samples designed to facilitate HPV research - is based
• Current R and D lead for the Scottish Bacterial STI Reference laboratory
• I am fortunate to sit on several national groups and steering committees associated with HPV infection and associated disease management including (but not confined to) the UK Cervical Screening Research Advisory Committee, the British Association for Sexual Health and HIV (BASHH) HPV Subgroup, the HPV sub committee of the Joint Committee for Vaccination and Immunisation and the Laboratory Technologies Subgroup of the UK Cervical Screening Programme
• I am an author of >100 original publications, reviews and book chapters on HPV and STIs
Title of your presentation:
Circulating Tumor Cell Capture, Interrogation, Imaging, Automated Analysis and Culture: New Tools and Biologic Insights
Circulating tumor cells (CTC) and Disseminated Tumor Cells (DTC) are important clinical biomarkers for cancer diagnosis, prognosis and target identification. A number of features of CTC and DTC that appear to have biologic significance have been described, including epithelial morphology, clustering/aggregates and quantification. We showed that DTC are enriched for the cancer stem cell phenotype, indicating that these cells are indeed the precursors to overt metastasis. Recently, we have described the presence of circulating Cancer Associated Fibroblasts (cCAF), alone and in clusters with CTC. cCAF appear to be important in cancer progression, and may form the “soil” that is carried from the primary to metastatic sites that allow the CTC “seeds” to proliferate. Our recent findings indicate that cCAFs also have distinct biologic potential to act as appropriate substrates for metastatic growth.
The analysis of CTC remains challenging due to the rarity of the cells (even using the most highly enriching platforms) and the heterogeneity of phenotype and epithelial marker status. Our group has made significant advances in CTC capture methods, providing the most efficient and enriching capture platform so far described. We have developed novel imaging systems that allow for the rapid acquisition of high-quality images, and we are working to apply Artificial Intelligence/Deep Learning to these images. We will discuss integrated platforms for capture and novel imaging of CTC/cCAF and efforts to automate the analysis of CTC/cCAF images. Our group has also developed highly efficient live CTC capture platforms, and we are now engineering specific microenvironments which could lead to expansion, propagation, and creation of an important new biospecimen for cancer discovery.
Richard J. Cote, M.D., FRCPath, FCAP is Chair and Professor of the Department of
Pathology and Immunology at Washington University in St. Louis School of Medicine.
Prior to this he was the Joseph R. Coulter Jr. Chair of the Department of Pathology,
Professor of Biochemistry and Molecular Biology, and Founding Director of the Dr. John
T. Macdonald Foundation Biomedical Nanotechnology Institute at the University of Miami
Miller School of Medicine. He is a board-certified Pathologist, serving over 25 years in
senior academic, consultative, and director/clinical roles with leading universities,
hospitals and healthcare enterprises.
Dr. Cote obtained degrees in chemistry and biology at the University of California at Irvine and received his medical degree from the University of Chicago - Pritzker School of Medicine. He completed his residency at New York Hospital - Cornell University Medical College. His training included a clinical fellowship in pathology at Memorial Sloan- Kettering Cancer Center, a research fellowship in Human Tumor Immunology at Memorial Sloan-Kettering Cancer Center and a fellowship in Molecular Pathology at New York University School of Medicine. Prior to 2009, he was Professor, Departments of Pathology and Urology; Director, Genitourinary Cancer Program; Director, Laboratory of Immunology and Molecular Pathology; and Director of the USC Biomedical Nanoscience Initiative at the University of Southern California Keck School of Medicine. As Chair of Pathology at the University of Miami, Dr. Cote led a transformation of the department that resulted in an increase in revenues of over 400%, an improvement in NIH funding ranking of nearly 60 positions, and an improvement in outcomes for the training (residency) program. Under his leadership, the department was ompletely reorganized to deliver sub-specialty care, the infrastructure was built to serve the entire health system, totaling in all 6 hospitals and multiple outpatient sites. Under Dr. Cote’s leadership, the department consolidated operations across the systems, creating economies of scale that resulted in millions of dollars in savings to the health system. At Washington University, he has lead the transition to subspecialty care, and is recruiting some of the leading scientists and pathologists in the country.
Dr. Cote’s research is focused on the elucidation of cellular and molecular pathways of tumor progression and response to therapy. He has special interests in micrometastases and circulating tumor cell (CTC) detection and characterization, the pathology of breast and genitourinary tumors and technology development. Most recently, he and his colleagues at the University of Miami, USC, Caltech, and UC Berkeley developed nanoscale technologies for cancer diagnostic applications, including bionanosensors for the detection of serum tumor markers, and technologies for the capture, characterization and propagation of CTC. As a result of these efforts, he established the Biomedical Nanoscience Program at USC and the Dr. John T. Macdonald Biomedical Nanotechnology Institute at the University of Miami (BioNIUM, for which Cote procured a $7.5 million naming gift), for the development of novel diagnostic platforms and targeted therapeutics. He is the recipient of over $190 million in research support, including nearly $43 million as principal investigator (primarily from NIH), and holds numerous patents for cancer related and nanoscale technologies. He has led three of the largest clinical trials in breast, lung and bladder cancer, which were based on discoveries from his research. He is the author of over 300 publications, including several standard textbooks, and participates on numerous scientific advisory boards for academia and industry.
Dr. Cote is a frequent lecturer and serves as a member and advisor to many national and international organizations, including the NCI. He is listed in “US News and World Report Top 1% of Doctors”, “Best Doctors in America”, “America’s Top Doctors”, “America’s Best in Medicine”, “Who’s Who Lifetime Achievement Award”, “Newsweek Health: Top Cancer Doctors”, and “South Florida Super Doctors”. He was awarded the 2013 Distinguished Alumnus of the Year by the School of Physical Sciences at the University of California, Irvine, was elected to the Association of American Physicians in 2010, and is a member of Phi Beta Kappa and the Alpha Omega Alpha Medical Honor Societies. Recently he was awarded the Miami Chamber of Commerce Bio-Medical Healthcare Heroes Award (2015) and Society for Personalized Nano-Medicine Excellence Service Award (2016).
Dr. Cote is the founder of several technology-based companies, including Impath, Inc., Clarient, Filtini and Sensitini. Impath, one of the first companies to bring esoteric testing for cancer analysis to the market, was founded in 1988 and underwent an IPO in 1996. It achieved a market cap of $1B, and was acquired by Genzyme in 2004. Dr. Cote help to start an image analysis company, Chromavision, and in 2003 directed a re-engineering of the company and name change to Clarient, which brought high tech diagnostic capabilities to practicing pathologists and oncologists. After a successful expansion, Clarient, a publically traded company, was acquired by GE in 2009. Dr Cote has been an advisor to numerous biotech and biopharmaceutical companies, including Genentech, Roche, Lilly, Neoprobe, Johnson and Johnson Ortho Pharmaceuticals, and Abbott/Vysis.